Skip to main content

Takeda Licenses Use of Kinaxo Proteomics Platform

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies will make its KinaTor chemical proteomics technology available to Takeda San Diego researchers in drug discovery, preclinical research, and clinical development under an agreement announced this week.
 
Terms of the deal were not disclosed.
 
The KinaTor platform combines proprietary chemical proteomics technologies with mass spectrometry for the identification and characterization of a drug candidate’s native molecular targets in cell lines and tissue samples.
 
Takeda San Diego is a wholly owned subsidiary of Takeda Pharmaceutical, based in Osaka, Japan. Kinaxo is a privately held firm based in Martinsreid, Germany.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.